Barclays analyst Stephanie Davis assigned a Buy rating to Health Catalyst (HCAT – Research Report) yesterday and set a price target of $14.00. The company’s shares closed yesterday at $8.25.
Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Health Catalyst, and Computer Programs and Systems. According to TipRanks, Davis has an average return of -6.5% and a 42.21% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Health Catalyst with a $12.27 average price target, which is a 48.73% upside from current levels. In a report released on February 26, Wells Fargo also maintained a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Health Catalyst’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $75.08 million and a GAAP net loss of $30.31 million. In comparison, last year the company earned a revenue of $69.16 million and had a GAAP net loss of $35.78 million
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HCAT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst (HCAT) Company Description:
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT:
- Health Catalyst price target lowered to $15 from $17 at Piper Sandler
- Health Catalyst price target lowered to $11 from $12 at Canaccord
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst sees FY24 revenue $304M-$312M, consensus $324.49M
- Health Catalyst sees Q1 revenue $72.5M-$76.5M, consensus $78.99M
